1. Stria Lithium (TSXV:SRA)

Year-to-date gain: 708.33 percent
Market cap: C$19.11 million
Share price: C$0.48

Stria Lithium is a Canadian exploration company focused on developing domestic lithium resources to support the growing demand for electric vehicles and lithium-ion batteries. The company’s flagship Pontax Central lithium project spans 36 square kilometers in the Eeyou Istchee James Bay region of Québec, Canada.

Cygnus Metals (TSXV:CYG,ASX:CY5,OTCQB:CYGGF) has an earn-in agreement with Stria to earn up to a 70 percent interest in Pontax Central. Cygnus completed the first stage in July 2023, acquiring a 51 percent interest by investing C$4 million in exploration and issuing over 9 million shares to Stria.

In May 2025, Stria and Cygnus agreed to extend the second stage of Cygnus’s earn-in agreement on the Pontax Central lithium project by 24 months. The second stage involves a further C$2 million in exploration spending and C$3 million in a cash payment.

Through its joint venture with Cygnus, Stria has outlined a JORC-compliant maiden inferred resource for Pontax Central of 10.1 million metric tons grading 1.04 percent lithium oxide.

In March, Stria closed a non-brokered private placement for C$650,000. The funds will be used in part for the evaluation of new mineral opportunities, according to the company.

Shares of Stria registered a year-to-date high of C$0.50 on December 30, 2025, coinciding with lithium carbonate prices rising to a near 24 month high.

2. Consolidated Lithium Metals (TSXV:CLM)

Year-to-date gain: 350 percent
Market cap: C$20.51 million
Share price: C$0.045

Consolidated Lithium Metals is focused on acquiring, developing and advancing lithium projects in Québec. Its properties — Vallée, Baillargé, Preissac-LaCorne and Duval — are located within the spodumene-rich La Corne Batholith area, near the restarted North American Lithium mine, a key area in Canada’s growing lithium sector.

Consolidated Lithium started the year with a C$300 million private placement earmarked for working capital and general corporate purposes.

In July, the company commenced a summer exploration program at the Preissac project, excavating a 100 by 30 meter trench in an area with a known lithium soil anomaly, uncovering an 18 meter wide pegmatite body at surface.

At the end of August, Consolidated Lithium signed a non-binding letter of intent with SOQUEM, a subsidiary of Investissement Québec, to acquire an option to earn up to an 80 percent interest in the Kwyjibo rare earths project.

The project is located roughly 125 kilometers northeast of Sept-Îles in Québec’s Côte-Nord region.

Under the deal, which was finalized in November, Consolidated Lithium will become operator of the project and can earn an initial 60 percent stake over five years through a combined C$23.15 million in cash payments, share issuances and project expenditures.

A significant portion of those funds will be invested in advancing Kwyjibo through stages including negotiating and finalizing an agreement with the Innu of Uashat mak Mani-Utenam, a metallurgical study and environmental permitting.

Upon completion, the partners will form a joint venture, and Consolidated will have the option to increase its interest to 80 percent by investing C$22 million over a further three years.

An uptick in lithium prices in October helped Consolidated shares rally to a year-to-date high of C$0.06 several times between October 22 and November 3.

3. Lithium South Development (TSXV:LIS)

Year-to-date gain: 330 percent
Market cap: C$48.76 million
Share price: C$0.43

Canada-based Lithium South Development currently owns 100 percent of the HMN lithium project in Argentina’s Salta and Catamarca provinces, situated in the heart of the lithium-rich Hombre Muerto Salar.

The project lies adjacent to South Korean company POSCO Holdings’ (NYSE:PKX,KRX:005490) billion-dollar lithium development to the east.

Exploration has defined a resource of 1.58 million metric tons of lithium carbonate equivalent (LCE) at an average grade of 736 milligrams per liter lithium, with the majority in the measured category. A preliminary economic assessment outlines the potential for a 15,600 metric ton per year lithium carbonate operation.

In January 2024, Lithium South and POSCO signed an agreement to jointly develop the HMN lithium project. Under the deal, the companies will share production 50/50 from the Norma Edith and Viamonte blocks in Salta and Catamarca, resolving overlapping claims.

As for 2025, in June Lithium South’s shares tripled to C$0.30 after it received positive news regarding its environmental impact assessment.

Lithium South shared a huge update in July that changed its trajectory; the company received a non-binding cash offer of US$62 million from POSCO to purchase its lithium portfolio, including the HMN project.

POSCO would acquire Lithium South’s wholly owned subsidiary NRG Metals Argentina, which holds the HMN project and all of Lithium South’s other concessions, namely the Sophia I–III and Hydra X–XI claims.

The 60 day due diligence period concluded in late September, and on November 12, Lithium South announced a share purchase agreement to sell its Argentinian lithium portfolio to POSCO Argentina for US$65 million.

Company shares climbed to C$0.44 the next day, while its highest close of the year, C$0.45, came on December 24.

Lithium South officially signed the deal on December 8, with its closing subject to several approvals. Following the transaction’s completion, Lithium South plans to de-list from the TSXV and begin dissolution proceedings.

In connection with the news, the company intends to buy back all common shares at a price of C$0.505.

4. Standard Lithium (TSXV:SLI)

Year-to-date gain: 190 percent
Market cap: C$1.47 billion
Share price: C$6.15

Standard Lithium is a US-focused lithium development company advancing a portfolio of high-grade lithium brine projects with an emphasis on sustainability and commercial-scale production.

The company employs a fully integrated direct lithium extraction process and is developing its flagship Smackover Formation assets in Arkansas and Texas, including the South West Arkansas project. The projects are a partnership with Equinor ASA, under the 55/45 joint venture subsidiary Smackover Lithium.

In April, its South West Arkansas project was one of 10 US critical minerals projects designated for fast tracking under FAST-41.

On September 3, Standard Lithium reported results of its definitive feasibility study (DFS) for the South West Arkansas project. The DFS notes an initial capacity of 22,500 metric tons per year of battery-grade lithium carbonate, with first production targeted for 2028. The study outlines an operating life of over 20 years based on average lithium concentrations of 481 milligrams per liter, supported by detailed resource and reserve modeling. The company filed the DFS on October 14.

In late October, Standard Lithium reported the unanimous approval of the Arkansas Oil and Gas Commission for the company’s Integration Application for the project’s Reynolds brine unit, which is where the initial commercial phase of production is planned.

Standard is also actively exploring additional lithium brine opportunities in East Texas through the joint venture, and in November, Smackover Lithium filed the maiden inferred resource report for the Franklin project. The report highlights 2.16 million metric tons of LCE, 15.41 million metric tons of potash and 2.64 million metric tons of bromide contained in 0.61 square kilometers of brine volume.

The resource stands at an average lithium grade of 668 milligrams per liter, including a grade of 806 milligrams per liter at the Pine Forest 1 well, which the company states is North American’s highest concentration of lithium-in-brine.

The project covers roughly 80,000 acres, with 46,000 acres leased, and is poised to become the first phase in a broader East Texas expansion. Smackover Lithium ultimately aims to produce over 100,000 metric tons of lithium chemicals annually from its Texas operations.

On October 20, Standard closed a US$130 million underwritten public offering for 29,885,057 common shares, which will fund capital expenditures at the South West Arkansas project and the Franklin project.

Standard and Equinor ended the year advancing project financing for its South West Arkansas project, targeting up to US$1.1 billion in senior secured debt. The company has received over US$1 billion in combined interest from major export credit agencies, including the US EXIM Bank and Norway’s Eksfin.

The potential funds, alongside a US$225 million grant from the US Department of Energy, would support Phase 1 construction, which has an estimated US$1.45 billion in capital expenditures, FEED and feasibility study costs, and typical financing contingencies.

After climbing steeply starting in late September, the company’s shares hit a year-to-date high of C$7.64 on October 16.

5. Q2 Metals (TSXV:QTWO)

Year-to-date gain: 144.87 percent
Market cap: C$363.79 million
Share price: C$1.97

Exploration firm Q2 Metals is exploring three lithium properties — Cisco, Mia and Stellar — in the Eeyou Istchee James Bay region of Québec, Canada. Contained within the portfolio is the Mia trend, which spans over 10 kilometers, while the Stellar lithium property comprises 77 claims and located 6 kilometers north of the Mia property.

In 2024, Q2 Metals acquired Cisco lithium property and spent the rest of the year exploring the area. The work led to Q2 acquiring a 100 percent interest in 545 additional mineral claims, tripling its land position at the Cisco lithium property.

A subsequent company update reported that metallurgical testing on drill core from its 2024 exploration work confirmed that spodumene is the primary lithium-bearing mineral within pegmatite at the project.

The company performed multiple drill campaigns in 2025, including a winter diamond drilling program. Over the course of the year, Q2 defined an exploration target and reported a series of positive results from test work and drilling at the project.

The most recent announcement, released December 3, singled out results from drill hole 44 as the ‘widest continuous spodumene pegmatite interval’ identified at the property. The hole intersected 457.4 meters of continuous mineralization with an average grade of 1.65 percent lithium oxide.

‘Drill hole 44 further showcases the Cisco project as a globally significant hard rock lithium discovery. The results to date will underpin the inaugural Mineral Resource Estimate, which we expect to announce in the first quarter of 2026, as we continue to advance Cisco,’ wrote Alicia Milne, president and CEO of Q2 Metals.

The company’s share price began climbing in late October following the news that it added Keith Phillips, CEO of Piedmont Lithium from 2017 to 2025, to its board of directors.

Propelled by the board addition and the drilling results results, shares of Q2 Metals ended 2025 on a high note, registering a year-to-date high of C$1.95 on December 30.

European cannabis legalization and international growth

2025 brought incremental legalization or medical frameworks in multiple jurisdictions, including Czechia, Malta, Poland, Switzerland and Luxembourg, broadening the investable global footprint.

This continental momentum has directly boosted North American producers through export ramps and licensing deals, with Canadian licensed producers capturing 43 percent of Germany’s Q2 imports alone.

The country’s CanG framework and adult‑use reform, which came into effect in April 2024, have made it Europe’s most important legal market, with 2025 medical sales expected to see explosive year-on-year growth.

Investor takeaway

2025 marked a transformative year for cannabis, with regulatory breakthroughs and market maturation set against the backdrop of volatility. Trump’s execuctive order has brought new life into the sector in the US with the promise of not only banking and tax relief, but also bipartisan momentum for normalization; however, investors remain cautious.

“Everybody is waiting for it to be real and for it to be completed. Because even though we think the executive order was huge … nothing’s complete yet. Nothing’s official yet,” explained Ahrens.

Looking to 2026, he emphasized that the path forward for cannabis isn’t a straight line, but rather a series of volatile ‘waves’ tied to incremental regulatory milestones. Ahrens anticipates that while the finalization of Schedule III should trigger an initial move, it is merely the first domino; subsequent upside depends on the DoJ providing clear guidance for state-legal adult-use programs and the eventual passage of banking reform.

While he does foresee cannabis stocks uplisting to major exchanges, and Big Pharma companies beginning to make acquisitions in the space, Ahrens remains cautious about timing, noting that even with a signed order, large institutional banks will likely keep the ‘blockade’ in place until the legal ink is truly dry.

Ultimately, while 2025’s executive action has established a concrete foundation for federal reform in the US, the cannabis sector remains poised in a state of high-stakes volatility, with its full maturation dependent on official completion of milestones in 2026 and beyond.

1. MDxHealth (NASDAQ:MDXH)

Year-on-year gain: 50.86 percent
Market cap: US$173.24 million
Share price: US$3.50

MDxHealth is a commercial-stage precision diagnostics company specializing in molecular tests for urologic cancers, particularly prostate cancer, using genomic, epigenetic and exosomal technologies. Its US headquarters and operations are located in Irvine, California.

The company offers non-invasive and tissue-based diagnostic assays that run on standard PCR platforms.

In September, MDxHealth acquired Exosome Diagnostics from Bio-Techne (NASDAQ:TECH) for US$15 million, adding the ExoDx Prostate urine test to its portfolio. The deal also includes a CLIA-certified clinical laboratory and related assets. The deal is expected to generate over US$20 million in revenue in 2026.

2. KORU Medical Systems (NASDAQ:KRMD)

Year-on-year gain: 50.13 percent
Market cap: US$269.6 million
Share price: US$5.82

KORU Medical Systems develops and manufactures medical devices and supplies in the US and internationally, with a focus on mechanical infusion products. Its Freedom Syringe Infusion System first received FDA clearance in 1994.

Based on this system, its primary products include the Freedom60 and FreedomEdge syringe infusion systems, Precision Flow Rate Tubing and High-Flo Subcutaneous Safety Needle Sets.

KORU Medical Systems submitted a 510(k) premarket notification to the FDA on December 30, 2025, seeking clearance for its FreedomEdge system to deliver Phesgo — a HER2+ breast cancer targeted biologic — subcutaneously, targeting infusion centers to cut chair time and boost efficiency.

The company stated this is part of its strategy to expand the indications of FreedomEdge to the wider oncology infusion center market.

3. Vivani Medical (NASDAQ:VANI)

Year-on-year gain: 1.71 percent
Market cap: US$86.81 million
Share price: US$1.19

Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, long-term subdermal drug implants using its proprietary NanoPortal technology to treat chronic conditions like obesity and type 2 diabetes.

Headquartered in Alameda, California, Vivani focuses on GLP-1 implants that provide steady drug release over six months to improve adherence and tolerability compared to daily pills or weekly injections.

In August, Vivani Medical reported positive Phase 1 results from its LIBERATE-1 trial of the NPM-115 exenatide implant, confirming safety and steady drug release for obesity treatment without major side effects.

The company plans to rapidly advance its NPM-139 semaglutide implant after it achieved preclinical results of sustained 20 percent weight loss. It is planning a Phase 1 clinical study in the first half of 2026.

1. Galectin Therapeutics (NASDAQ:GALT)

Year-to-date gain: 211.45 percent
Market cap: US$263.08 million
Share price: US$4.08

Galectin Therapeutics is developing therapies for patients with chronic liver disease and cancer.

The clinical-stage biopharma company’s lead drug candidate, carbohydrate-based belapectin, targets multiple inflammatory, fibrotic and malignant diseases by inhibiting the galectin-3 protein. Belapectin has been granted fast-track designation by the FDA.

In 2025, Galectin Therapeutics reported positive topline data from its Phase 2b/3 trial evaluating the efficacy and safety of using belapectin intravenously in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hyper tension. The results demonstrated that belapectin significantly reduced the development of new esophageal varices and stabilized liver stiffness, demonstrating potential to halt the progression of MASH cirrhosis.

Galectin is currently designing its pivotal Phase 3 study intended to support a formal new drug application. Based on a December 2025 response from the FDA, the company said it believes it has achieved alignment with the agency on the patient population for its upcoming registration-level trials.

2. CytomX Therapeutics (NASDAQ:CTMX)

Year-to-date gain: 136.63 percent
Market cap: US$375.74 million
Share price: US$2.38

CytomX Therapeutics is a clinical-stage biopharma firm with a focus on developing safer, more effective oncology treatments. It collaborates with a number of leading oncology firms, including Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA).

The company’s pipeline is based on its PROBODY therapeutic platform, which it uses to produce localized biologics that target tumors. This includes multiple treatment modalities such as antibody-drug conjugates, T-cell engagers and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051 and CX-801.

In mid-May 2025, CytomX’s share price shot up significantly after the company provided its Q1 business update and closed on a US$100 million underwritten offering of common stock.

In the update, CytomX included positive interim clinical results for an ongoing Phase 1 dose escalation study of its lead candidate, CX-2051, in advanced colorectal cancer. The company has initiated further Phase 1 dose expansions, with data expected out by Q1 2026. In its Q3 update, CytomX reported it plans to initiate a Phase 1b study of CX-2051 in combination with bevacizumab to treat colorectal cancer, also expected in the first quarter of the new year.

On May 19, the first patient was dosed in CytomX’s ongoing Phase 1 dose escalation study with CX-801 in combination with Merck & Company’s (NYSE:MRK) Keytruda in patients with metastatic melanoma. The company released initial translational data in November.

3. Eton Pharmaceuticals (NASDAQ:ETON)

Year-to-date gain: 25.37 percent
Market cap: US$450.53 million
Share price: US$16.80

Eton Pharmaceuticals is a high-growth pharmaceutical company developing treatments for rare diseases. Headquartered in Deer Park, Illinois, the company has successfully transitioned from a development-stage firm into a commercially focused entity with a diversified portfolio of orphan drugs.

2025 included the successful launch of KHINDIVI, the first FDA-approved oral solution formulation of hydrocortisone, in June. KHINDIVI was approved in May for pediatric patients five and older with adrenocortical insufficiency. The company is looking to expand the indication to younger patients with a revised formulation, and a bioequivalence study is expected to begin in early 2026.

The year also included high-performing relaunches of acquired assets Increlex, which treats a rare condition in which a child’s body does not produce enough growth factor-1, and the zinc therapy Galzin, a maintenance treatment for Wilson disease.

As of December, its portfolio included eight commercial products and five in its pipeline. The FDA is reviewing its new drug application for ET-600, with a decision scheduled for late February.

4. Fennec Pharmaceuticals (NASDAQ:FENC)

Year-to-date gain: 20.91 percent
Market cap: US$262.54 million
Share price: US$7.69

Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on preventing ototoxicity, meaning permanent hearing loss, in pediatric cancer patients undergoing cisplatin-based chemotherapy.

The company’s sole commercial product, Pedmark, is the first and only FDA-approved therapy specifically indicated to reduce the risk of hearing loss associated with cisplatin in patients one month of age and older with non-metastatic solid tumors.

Fennec experienced a pivotal year in 2025, marked by record revenue growth, entry into international markets and the elimination of corporate debt.

Additionally, data from a Phase 2/3 clinical study in Japan showed a significant reduction in the percentage of patients who experienced hearing loss, setting the stage for a 2026 global registration.

The company also began exploring its first major expansion into the adult cancer market through a new trial in metastatic testicular cancer.

5. Zevra Therapeutics (NASDAQ:ZVRA)

Year-to-date gain: 5.25 percent
Market cap: US$496.54 million
Share price: US$8.82

Zevra Therapeutics is a commercial-stage rare disease company that utilizes data-driven strategies to develop and commercialize transformational therapies for ultra-rare conditions.

Formerly known as KemPharm, the company rebranded in 2023 to reflect its evolution into a fully integrated pharmaceutical entity with a focus on high-unmet-need pediatric and metabolic disorders.

At the end of December, Zevra executed a strategic distribution agreement with Uniphar to provide its flagship product, Miplyffa, to patients outside of the US and Europe, broadening the drug’s global footprint. Miplyffa was approved by the FDA in 2024, and is indicated as a treatment for Niemann-Pick disease type C administered in combination with miglustat.

This announcement followed a strong Q3, in which the company reported a 605 percent year-over-year revenue increase, largely driven by the early success of Miplyffa.

Investor Insight

Juggernaut Exploration is an early-stage explorer and project generator with a compelling investment story, focused on unlocking high-grade precious and base metal discoveries in the prolific Golden Triangle of northwestern British Columbia.

Overview

Juggernaut Exploration(TSXV:JUGR,OTCQB:JUGRF,FSE:4JE) is a precious metals explorer focused on northwestern British Columbia’s Golden Triangle, a globally recognized district for world-class porphyry, VMS, and high-grade gold systems. The company operates in a geopolitically stable jurisdiction with excellent infrastructure, adjacent to Newmont’s Galore Creek project and in proximity to major road and airstrip developments.

The company controls three 100 percent owned projects – Big One, Midas, and Bingo – totaling nearly 60,000 hectares in the heart of British Columbia’s most prolific mineral belt.

The company’s current strategy focuses on aggressive exploration at its flagship Big One project, where the rapid abatement of glacial cover led to the discovery of over 200 mineralized veins in a matter of days. The scale of the system, coupled with strong geophysical and geochemical signatures, points to a significant buried porphyry system.

Backed by world-renowned geologist Dr. Quinton Hennigh, Juggernaut was founded by the team behind Goliath Resources, which returned 2,400 percent to early investors in just 20 months.

Company Highlights

• The Big One property has uncovered a 15-km gold-rich porphyry system, described as a “highway of gold,” adjacent to Newmont’s $100 billion Galore Creek project.
• Founded by the team behind Goliath Resources, which returned 3,400 percent to early investors in just 20 months. World-renowned geologist Dr. Quinton Hennigh supports Juggernaut.
• Crescat Capital is a cornerstone investor, holding a 19.99 percent stake and providing both financial and technical backing.
• The company controls three 100 percent owned projects – Big One, Midas, and Bingo – totaling nearly 60,000 hectares in the heart of the Golden Triangle in British Columbia.
• With $12.5 million recently raised, the 2025 field season is fully funded. The upcoming campaign aims to scale and define the scope of the porphyry system discovered in just five days of boots-on-the-ground work.
• 5-Year Drill Permit Secured: A valid 5-year drill permit is in place for the Big One Property in British Columbia’s Golden Triangle, in good standing through March 31, 2031.
• 2026 Inaugural Drill Program: The company is planning a fully funded drill program to test multiple gold-rich, shear-hosted vein targets identified at surface within the newly discovered, district-scale Eldorado System and Gold Swarm discoveries, targeting depth extensions in the third dimension.
• Over 70 percent of the company’s shares are held by management, insiders and accredited investors. The company is debt-free.

Key Projects

Big One

The Big One project is Juggernaut’s flagship asset located in the heart of British Columbia’s Golden Triangle. The property spans 36,989 hectares of world-class geological terrain, with 95 percent of its remaining unexplored.

The project benefits from rapid glacial and snowpack abatement, which has recently exposed a vast mineralized system previously hidden under ice. This includes the newly identified Eldorado porphyry system, a high-grade, multi-kilometer corridor with grades reaching up to 79.01 grams per ton (g/t) gold and 3,157 g/t silver. More than 200 quartz-sulphide veins, containing semi-massive to massive chalcopyrite, sphalerite and galena, have been identified within a 4 km x 1 km alteration footprint, with coincident geophysical anomalies suggesting the presence of a large, buried mineralizing system at depth.

The Big One project qualifies for the Critical Mineral Exploration Tax Credit and is strategically located adjacent to key infrastructure, including the Scud airstrip and a new $45 million government-funded road within 12 km of the site.

In 2025, Juggernaut Exploration received a 5-year drill permit for the Big One property. The permit is in good standing until March 31, 2031. The company is planning a drill program targeting several extensive gold-rich shear-hosted veins confirmed on surface in the newly discovered district-scale Eldorado System and Gold Swarm discoveries. These strong drill targets are planned to be tested in the third dimension during the fully-funded inaugural drill program in 2026.

Newly discovered drill ready El Dorado System

Midas

The Midas property covers 20,803 hectares in a geologically favorable setting for volcanogenic massive sulphide (VHMS) deposits, particularly those resembling the high-grade Eskay Creek system. Drilling at the Kokomo zone has intercepted significant VHMS-style mineralization, including standout results such as 8.27 g/t gold equivalent over 11.03 meters (MD-24-47) and 6.85 g/t gold over 9 meters (MD-18-08). The mineralized zone remains open to the north, and the company plans to step out aggressively with additional drilling.

Midas is considered a strong near-term value generator with potential for scale through further discovery.

Bingo

The Bingo property, although smaller in footprint at 1,008 hectares, is located in a structurally favorable setting for shear-hosted gold systems. The project features a 700-meter x 400-meter mineralized zone characterized by consistent sulphide mineralization. Sampling has confirmed an average mineralized width of 7 meters with grades averaging 5.67 g/t gold equivalent. The presence of strong K-spar alteration in the northeast quadrant of the property suggests proximity to a porphyry feeder system, making Bingo a compelling target for both high-grade, shear-hosted and porphyry-style exploration.

Management Team

Manuele (Lele) Lazzarotto – President and Chief Operating Officer (COO)

Manual Lazzarotto, Ph.D., has over a decade of experience in the mineral exploration industry, taking projects from inception to defined deposits. He has extensive experience in volcanogenic massive sulphide deposits and gold systems in Canada. Most recently, Lazzarotto has acted as chief geologist, instrumental in the discovery of Goliath Resources’ Surebet Discovery from 2019 to 2025. He holds a BSc and an MSc in Earth Sciences from ETH Zurich, Switzerland, and a PhD in Metamorphic Petrology from the University of Calgary, Canada.

Dan Stuart – CEO and Director

Dan Stuart has over 30 years of experience in capital markets, having raised more than $500 million for natural resource companies. He is a founding member and financier of several private mineral syndicates, including the J2 Syndicate behind Goliath Resources. Stuart is recognized for his investor acumen and has established strong institutional relationships across North America, Europe, Asia, and the Middle East. Under his leadership, Juggernaut secured cornerstone funding from Crescat Capital and Dr. Quinton Hennigh while simultaneously building a platform for rapid discovery-driven growth.

Jim McCrea – Director

Jim McCrea brings 25 years of exploration and resource estimation experience. Notably, he worked on orebody modeling and resource estimation at Cumberland Resources, which was acquired by Agnico Eagle for $710 million. His deep expertise in geology and modeling helps guide exploration targeting and resource development.

William Jung – Director and CFO

A former chartered accountant with over 35 years of experience in finance, William Jung has managed several publicly listed companies on the TSX. His oversight ensures financial discipline, compliance, and strategic capital allocation.

Peter Bryant – Director

Peter Bryant is a seasoned international investment banker with 45 years of experience, including senior roles at Standard Chartered Group, Hill Samuel Group, and Guinness Mahon Holdings in London. His presence brings strong governance and capital markets insights to the board.

Chris Verrico – Director

Chris Verrico has over two decades of experience managing mineral exploration and infrastructure projects in remote northern regions, including British Columbia, Yukon and Nunavut. His knowledge of field operations and community engagement is critical to project execution.

Bill Chornobay – Program Manager

Bill Chornobay has over 30 years of experience in mineral exploration and has been directly involved in discoveries resulting in more than $1 billion in value. He played a pivotal role in the Surebet discovery for Goliath Resources and now leads on-ground execution at Juggernaut.

Dr. Quinton Hennigh – Technical Advisor

A globally respected exploration geologist, Dr. Quinton Hennigh has over 30 years of experience with major mining companies, including Homestake, Newcrest and Newmont. He is currently the chairman of Novo Resources and serves as a technical advisor to Crescat Capital. His guidance has helped validate and shape the exploration strategy at Juggernaut.

Dr. Manuele Lazzarotto – Senior Consulting Geologist

Dr. Manuele Lazzarotto has eight years of experience advancing early-stage exploration projects into defined resources, particularly in VMS and gold systems. He played a critical technical role in the Surebet discovery and brings valuable geological and structural insight to Juggernaut’s targeting approach.